Abdulhassan Saad, MD
Internal Medicine · Dearborn, MINPI 1447546593
Payments from drug & device makers
Across 701 payments — averaging $16,340 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7.7M
- Pfizer$1.5M
- Seqirus USA Inc$586K
- Lexicon Pharmaceuticals, Inc.$337K
- Beigene, Ltd.$310K
- Vertex$294K
- plus $776K from 31 others
Across 19 payments — averaging $8898.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$100K
- Orexo US, Inc.$69K
What the payments were for
- Consulting fees$8403%
- Speaking & faculty fees$23,10081%
- Travel & lodging$1110%
- Food & beverage$3,63113%
- Education$1651%
- Gifts$5062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 33 | $7,672,473 |
| Pfizer | 86 | $1,478,619 |
| Seqirus USA Inc | 222 | $585,926 |
| Lexicon Pharmaceuticals, Inc. | 34 | $337,350 |
| Beigene, Ltd. | 16 | $309,870 |
| Vertex | 2 | $294,264 |
| Biogen | 2 | $190,699 |
| Sanofi | 35 | $183,278 |
| OPKO Pharmaceuticals, LLC | 4 | $115,373 |
| Sanofi US Services Inc. | 24 | $96,733 |
| Chiesi USA, Inc. | 15 | $60,164 |
| Merck | 3 | $40,458 |
| Genentech, Inc. | 12 | $38,487 |
| Partner Therapeutics, Inc. | 6 | $22,683 |
| Alkermes, Inc. | 37 | $18,856 |
| MDD US Operations, LLC | 26 | $6,452 |
| GSK | 47 | $773 |
| Novo Nordisk | 63 | $742 |
| USWM, LLC | 4 | $612 |
| Watermark Medical, Inc. | 1 | $156 |
| AstraZeneca | 6 | $111 |
| Astellas Pharma US Inc | 1 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $70 |
| Integra Lifesciences Corporation | 2 | $56 |
| Lilly USA, LLC | 3 | $47 |
| Amgen | 2 | $37 |
| Orexo US, Inc. | 2 | $35 |
| Indivior Inc. | 2 | $30 |
| Exact Sciences | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| IBSA Pharma Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$18,615
- Lucemyra/Lofexidine$5,375
- LUCEMYRA$600
- ZIMHI$506
- TRELEGY ELLIPTA$250
- ARES HOME SLEEP TESTING DEVICE$156
How this compares
$11,454,615 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $55,766 |
| VivitrolNaltrexone Microspheres | 22 | $34,121 |
| LinzessLinaclotide | 51 | $27,886 |
| JardianceEmpagliflozin | 48 | $27,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $21,051 |
| TrulicityDulaglutide | 20 | $20,909 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 179 | $19,403 |
| EliquisApixaban | 24 | $18,402 |
| FarxigaDapagliflozin Propanediol | 23 | $12,917 |
| JanuviaSitagliptin Phosphate | 19 | $10,096 |
| XareltoRivaroxaban | 15 | $8,128 |
| MyrbetriqMirabegron | 14 | $6,308 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $4,197 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $4,115 |
| Atorvastatin Calcium | 359 | $3,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $742 | $55,76660 claims |
| Alkermes, Inc.Vivitrol | $18,856 | $34,12122 claims |
| Boehringer IngelheimJardiance | $23 | $27,71548 claims |
| GSKTrelegy Ellipta | $773 | $21,05134 claims |
| Lilly USA, LLCTrulicity | $47 | $20,90920 claims |
| PfizerEliquis | $1,478,619 | $18,40224 claims |
| AstraZenecaFarxiga | $111 | $12,91723 claims |
| MerckJanuvia | $40,458 | $10,09619 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $6,30814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Dearborn
- Ali HazimehDearborn$1.5M
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.